...
机译:基于片段的吡唑吡啶作为JAK1抑制剂具有优异的亚型选择性
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
LEO Pharma AS DMPK DK-2750 Ballerup Denmark;
LEO Pharma AS Skin Res DK-2750 Ballerup Denmark;
LEO Pharma AS Skin Res DK-2750 Ballerup Denmark;
LEO Pharma AS Skin Res DK-2750 Ballerup Denmark;
GVK Biosci Private Ltd Med Chem Hyderabad 500076 India;
GVK Biosci Private Ltd Med Chem Hyderabad 500076 India;
LEO Pharma AS MedChem 2 DK-2750 Ballerup Denmark;
机译:基于片段的吡唑吡啶作为JAK1抑制剂具有优异的亚型选择性
机译:基于同源性模型的亚型选择性腺苷受体配体的基于片段的发现
机译:新型吡唑的合成与生物学评价[1,5-A]嘧啶:发现jak1jh2伪转酶和vps34的选择性抑制剂的发现
机译:通过碎片的药物设计发现新型α-淀粉酶抑制剂作为两种糖尿病疗法
机译:使用基于片段的线索发现进行金属酶抑制剂的设计和开发。
机译:基于片段的选择性和细胞活性苯二氮杂酮的发现CBP / EP300溴域抑制剂(CPI-637)
机译:基于片段的吡唑吡啶作为JAK1抑制剂具有优异的亚型选择性